Background
Bremelanotide (PT-141) is a cyclic heptapeptide melanocortin receptor agonist — a metabolite of the tanning peptide Melanotan II — developed by Palatin Technologies for sexual dysfunction. Unlike PDE5 inhibitors (sildenafil, tadalafil), which act peripherally on vascular smooth muscle, PT-141 acts centrally via hypothalamic MC3R and MC4R receptors to initiate the sexual response cascade.
Prior animal work had shown that MC4R agonism in the paraventricular nucleus (PVN) triggers spontaneous erection in rats through a nitric oxide-dependent pathway. This Phase IIb study assessed whether the mechanism translated to clinically relevant efficacy in human males with ED.
Methods
324 men with erectile dysfunction (both psychogenic and organic) were enrolled in a multicenter, double-blind, placebo-controlled crossover study. Participants received intranasal PT-141 (1.25 mg, 4 mg, or 7.5 mg) or placebo during in-clinic sexual stimulation sessions.
Key assessments:
- RigiScan continuous nocturnal/in-clinic penile tumescence monitoring
- International Index of Erectile Function (IIEF-EF subscale)
- Successful intercourse attempt rate in home setting (subset)
Key Findings
Erectile Response (RigiScan):
- At 7.5 mg: 47% of subjects achieved an erection ≥60% rigidity lasting ≥10 minutes versus 17% with placebo (p < 0.001)
- Onset of response: median 40–60 minutes post-administration
- Duration: response persisted for up to 4–6 hours, distinguishing it from shorter-acting agents
IIEF-EF Domain:
| Dose | IIEF-EF Change | vs. Placebo |
|---|---|---|
| Placebo | +1.2 pts | — |
| 1.25 mg | +2.4 pts | p = ns |
| 4 mg | +4.1 pts | p < 0.05 |
| 7.5 mg | +6.3 pts | p < 0.001 |
Psychogenic vs. Organic ED:
- PT-141 was effective across ED etiology subtypes, including men who had failed PDE5 inhibitors
- 12% of prior PDE5 non-responders achieved successful erection with 7.5 mg PT-141
Tolerability:
- Most common adverse event: transient nausea (21% at 7.5 mg, dose-dependent)
- Flushing and headache in <10% of subjects
- No cardiovascular hemodynamic effects of clinical concern at doses studied
Mechanistic Significance
PT-141’s central mechanism offers a distinct approach compared to PDE5 inhibitors:
| Feature | PT-141 (Bremelanotide) | PDE5 Inhibitors |
|---|---|---|
| Site of action | CNS (hypothalamic MC3R/MC4R) | Peripheral (penile vasculature) |
| Stimulation requirement | Reduced (central initiation) | Required (NO-cGMP amplification) |
| Psychogenic ED | Directly addresses | Less effective |
| PDE5 non-responders | Potentially active | NA |
| Cardiovascular interactions | Minimal | Contraindicated with nitrates |
Clinical Significance
- Alternative for PDE5 failures: The approximately 30% of ED patients who do not respond to PDE5 inhibitors represent a significant unmet need; PT-141’s central mechanism offers an alternative pathway
- Psychogenic component: For men with predominantly psychogenic ED, a centrally acting agent that activates desire and arousal circuits may be more mechanistically appropriate than purely vascular agents
- Development trajectory: This trial directly supported the Phase III program, which ultimately led to FDA approval of subcutaneous bremelanotide for female HSDD (2019)
Limitations
- Crossover design with single-dose assessment; chronic efficacy and tolerance data absent
- Nausea at effective doses (7.5 mg) was a limiting tolerability concern that shaped subsequent dose and route development
- Intranasal delivery has variable bioavailability; subcutaneous formulation was later developed for more consistent pharmacokinetics
- RigiScan outcomes are intermediate endpoints; patient satisfaction and sexual quality of life were secondary